Home

At the request of the European Commission, the preliminary guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices are covering phthalates, which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties. Deadline for registration: 6 March 2019.

The Statement and Position Paper are published by the Commission’s Scientific Committee on Health, Environmental and Emerging Risks (SCHEER).

by Prof Peter Hoet, member of the Scientific Committee on Environmental and Emerging Risks (SCHEER) and Chair of the SCHEER Working Group on oil and gas, Medical Faculty, Katholieke Universiteit Leuven, Belgium.

This infographic explains and visualizes the Weight of Evidence process as applied by the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER)